Targeting MET in cancer: rationale and progress

By E. Gherardi, W. Birchmeier, C. Birchmeier, G. Woude. Nature Reviews. Cancer, 2012

827 citations recorded by the source corpus.

Subfields: Cell Biology, Hepatology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/08b0f442c5ffbb782f198c2f30c4afeab9a538bf

Citations in the corpus

• Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma (2018, neutral): “Mucosal inflammation 65 (14) 8 (2) 0 5 (2) 1 (<1) 0 Pyrexia 64 (14) 0 0 24 (10) 1 (<1) 0 Upper abdominal pain 63 (13) 3 (1) 0 31 (13) 0 0 Cough 63 (13) 1 (<1) 0 26 (11) 0 0 Peripheral edema 63 (13) 4 (1) 0 32 (14) 2 (1) 0 Stomatitis 63 (13) 8 (2) 0 5 (2) 0 0 Dyspnea 58 (12) 15 (3) 0 24 (10) 1 (<1) 0”
• Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer (2013, neutral): “It has been previously established that overexpression constitutively activates the MET receptor and is an oncogenic event in multiple cancer types (24, 25).”